6th NASH Roundtable™ Forum

Clinical Trials with Non-Invasive Tests (NITs) Instead of Histology: Fact or Fancy? 

November 5, 2022 | Washington, DC

NASH Roundtable forums are held twice a year, bringing together leading experts to facilitate advances in science, clinical research, and patient care for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The upcoming 6th Forum will facilitate a discussion on serum and imaging-based non-invasive testing, including regulatory considerations, within NAFLD/NASH clinical research.

Forum Topics to Include:

  • Where do we need to go with NITs?
  • Predicting patient response with serum and imaging-based NITs in NAFLD/NASH
  • Regulatory hurdles for NITs within drug development

Steering Committee


Vlad Ratziu, MD, PhD

Professor of Hepatology at Sorbonne Université and Pitié-Salpêtrière Hospital, Paris


Arun J. Sanyal, MD

Z. Reno Vlahcevic Professor of Medicine at Virginia Commonwealth University School of Medicine


Rohit Loomba, MD

Professor of Medicine, Director of Hepatology, at University of California at San Diego and Founding Director of the UCSD NAFLD Research Center


Marcus Hompesch, MD

President & CEO, ProSciento, Inc. and Editor-in-Chief, Endocrinology, Diabetes & Metabolism

Keynote Presenters

Alina Allen, MD Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology and the Director of the NAFLD Clinic at Mayo Clinic Rochester, Minnesota, USA

Prof Quentin M. Anstee, PhD, FRCP Professor of Experimental Hepatology, Faculty of Medical Sciences, Newcastle University, UK

Jeffrey V. Lazarus, PhD Co-director of the Viral and Bacterial Infections Programme at the Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain, and Senior Scholar at the CUNY Graduate School of Public Health and Health Policy, NY, USA

Richard Torstenson, PhD Senior Regulatory Affairs Director at AstraZeneca, Sweden

About the NASH Roundtable™

The NASH Roundtable™ was established in 2018 as a platform to stimulate collaboration and build consensus towards validated biomarkers and endpoints and to support the development of effective and safe treatments. Today the Roundtable consists of distinguished physicians, researchers, and clinical development experts from three continents brought together by their common commitment to steward advances in science, clinical research, and therapeutics for fibrotic diseases.